PMC:7402624 / 37277-37677 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T343","span":{"begin":121,"end":125},"obj":"Body_part"},{"id":"T344","span":{"begin":254,"end":257},"obj":"Body_part"},{"id":"T345","span":{"begin":283,"end":288},"obj":"Body_part"},{"id":"T346","span":{"begin":335,"end":340},"obj":"Body_part"}],"attributes":[{"id":"A343","pred":"fma_id","subj":"T343","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A344","pred":"fma_id","subj":"T344","obj":"http://purl.org/sig/ont/fma/fma84795"},{"id":"A345","pred":"fma_id","subj":"T345","obj":"http://purl.org/sig/ont/fma/fma68646"},{"id":"A346","pred":"fma_id","subj":"T346","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"duals over time. We then used the range of this variation over time to identify COVID-19 patients with changes in immune cell subpopulations beyond that expected in healthy subjects (see methods). Using this approach, ~50% of patients had an increase in HLA-DR+CD38+ non-naïve CD4 T cells over time, whereas in ~30% of patients, these cells were stable and, in ~20%, they decreased (Fig. 5E). For KI6"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1352","span":{"begin":261,"end":265},"obj":"Gene"},{"id":"1353","span":{"begin":277,"end":280},"obj":"Gene"},{"id":"1366","span":{"begin":89,"end":97},"obj":"Species"},{"id":"1367","span":{"begin":226,"end":234},"obj":"Species"},{"id":"1368","span":{"begin":319,"end":327},"obj":"Species"},{"id":"1378","span":{"begin":80,"end":88},"obj":"Disease"}],"attributes":[{"id":"A1352","pred":"tao:has_database_id","subj":"1352","obj":"Gene:952"},{"id":"A1353","pred":"tao:has_database_id","subj":"1353","obj":"Gene:920"},{"id":"A1366","pred":"tao:has_database_id","subj":"1366","obj":"Tax:9606"},{"id":"A1367","pred":"tao:has_database_id","subj":"1367","obj":"Tax:9606"},{"id":"A1368","pred":"tao:has_database_id","subj":"1368","obj":"Tax:9606"},{"id":"A1378","pred":"tao:has_database_id","subj":"1378","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"duals over time. We then used the range of this variation over time to identify COVID-19 patients with changes in immune cell subpopulations beyond that expected in healthy subjects (see methods). Using this approach, ~50% of patients had an increase in HLA-DR+CD38+ non-naïve CD4 T cells over time, whereas in ~30% of patients, these cells were stable and, in ~20%, they decreased (Fig. 5E). For KI6"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T290","span":{"begin":80,"end":88},"obj":"Disease"}],"attributes":[{"id":"A290","pred":"mondo_id","subj":"T290","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"duals over time. We then used the range of this variation over time to identify COVID-19 patients with changes in immune cell subpopulations beyond that expected in healthy subjects (see methods). Using this approach, ~50% of patients had an increase in HLA-DR+CD38+ non-naïve CD4 T cells over time, whereas in ~30% of patients, these cells were stable and, in ~20%, they decreased (Fig. 5E). For KI6"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T623","span":{"begin":121,"end":125},"obj":"http://purl.obolibrary.org/obo/GO_0005623"},{"id":"T624","span":{"begin":261,"end":265},"obj":"http://purl.obolibrary.org/obo/PR_000001408"},{"id":"T625","span":{"begin":271,"end":288},"obj":"http://purl.obolibrary.org/obo/CL_0000895"},{"id":"T626","span":{"begin":335,"end":340},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"duals over time. We then used the range of this variation over time to identify COVID-19 patients with changes in immune cell subpopulations beyond that expected in healthy subjects (see methods). Using this approach, ~50% of patients had an increase in HLA-DR+CD38+ non-naïve CD4 T cells over time, whereas in ~30% of patients, these cells were stable and, in ~20%, they decreased (Fig. 5E). For KI6"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T266","span":{"begin":258,"end":260},"obj":"Chemical"}],"attributes":[{"id":"A266","pred":"chebi_id","subj":"T266","obj":"http://purl.obolibrary.org/obo/CHEBI_73445"}],"text":"duals over time. We then used the range of this variation over time to identify COVID-19 patients with changes in immune cell subpopulations beyond that expected in healthy subjects (see methods). Using this approach, ~50% of patients had an increase in HLA-DR+CD38+ non-naïve CD4 T cells over time, whereas in ~30% of patients, these cells were stable and, in ~20%, they decreased (Fig. 5E). For KI6"}

{"project":"LitCovid-sentences","denotations":[{"id":"T215","span":{"begin":17,"end":196},"obj":"Sentence"},{"id":"T216","span":{"begin":197,"end":392},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"duals over time. We then used the range of this variation over time to identify COVID-19 patients with changes in immune cell subpopulations beyond that expected in healthy subjects (see methods). Using this approach, ~50% of patients had an increase in HLA-DR+CD38+ non-naïve CD4 T cells over time, whereas in ~30% of patients, these cells were stable and, in ~20%, they decreased (Fig. 5E). For KI6"}